Belapectin
Jump to navigation
Jump to search
Clinical data | |
---|---|
Other names |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
UNII |
Belapectin (also known as GR-MD-02) is a galectin-3 inhibitor developed by Galectin Therapeutics that is in clinical trials for the treatment of non-alcoholic steatohepatitis.[1][2][3][4]
References
- ^ Mireku, Akosua (26 June 2023). "NASH drugs race to cross the finish line". Pharmaceutical Technology. Retrieved 21 October 2023.
- ^ Al Attar, Atef; Antaramian, Ani; Noureddin, Mazen (3 April 2021). "Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis". Expert Review of Clinical Pharmacology. 14 (4): 457–464. doi:10.1080/17512433.2021.1894127.
- ^ Slack, R.J.; Mills, R.; Mackinnon, A.C. (January 2021). "The therapeutic potential of galectin-3 inhibition in fibrotic disease". The International Journal of Biochemistry & Cell Biology. 130: 105881. doi:10.1016/j.biocel.2020.105881.
- ^ Tapper, Elliot B.; Ufere, Nneka N.; Huang, Daniel Q.; Loomba, Rohit (May 2022). "Review article: current and emerging therapies for the management of cirrhosis and its complications". Alimentary Pharmacology & Therapeutics. 55 (9): 1099–1115. doi:10.1111/apt.16831. ISSN 0269-2813.
Categories:
- Drugs with non-standard legal status
- Infobox drug articles with non-default infobox title
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Multiple chemicals in Infobox drug
- Multiple chemicals in an infobox that need indexing
- Chemical articles with multiple CAS registry numbers
- Drugs missing an ATC code
- Articles containing unverified chemical infoboxes
- Lectins
- Experimental drugs developed for non-alcoholic fatty liver disease
- All stub articles
- Pharmacology stubs